Rutherrin Newsletter of Q3 2020:
‘Theralase® has completed one animal model and is diligently working to complete the second animal model. If successful, Theralase® will commence GLP toxicology studies in 2Q2021 with an aim to commencing a Phase Ib clinical study in GBM and NSCLC in 4Q2021.’
Newsletter of 4Q 2020:
‘Theralase® has completed one animal model and is working to complete the second animal model. If successful, Theralase® plans to commence a GLP toxicology studies with an aim to commencing a Phase Ib clinical study in GBM and NSCLC in 2022.’
(minor date slippage - par for the course)
Newsletter of Q1 2021:
Once Rutherrin®’s Maximum Tolerated Dose (“MTD”) and hence Human Equivalent Dose (“HED”) limits have been determined through non-Good Laboratory Practices (“GLP”) and GLP toxicology studies, Theralase® plans to inject Rutherrin® systemically into patients via a Phase Ib clinical study, planned for 2022, to allow localization to various cancer cells, including GlioBlastoma Multiforme (“GBM”) and Non-Small Cell Lung Cancer (“NSCLC”) and then activate Rutherrin® with radiation to safely and effectively, destroy the cancer of interest.
Newsletter of Q2 2021:
Strategic objectives
2. Successful completion of non-Good Laboratory Practices (“GLP”) and GLP toxicology studies to allow regulatory approval and commencement of a Phase Ib clinical study for Glio Blastoma Multiforme (“GBM”) and Non-Small Cell Lung Cancer (“NSCLC”).
(getting vaguer- no timelines anymore!)
More recent Newsletter dated the 7th of February 2022:
Currently in development of an injectable form of TLD-1433 (TLD-1433 + Transferrin = Rutherrin®) for additional cancer indications; specifically, Non-Small Cell Lung Cancer (“NSCLC”).
(Timeline gone - GBM removed - whatever happened to GLP?)
Enrique`s post of the 12th of April 2022:
‘After speaking with Dr Mandel, he let me know that the Company was very satisfied with the results and they were fully focused on this PH2 trial.’
Not this year for Rutherrin? Next year? Sometime? Never?
The prospect of an amenable affordable effective and disruptive treatment to address human suffering on an epic scale looks to be receding ever further into the distance. Out of all that Sherri has developed Rutherrin was my great hope for TLT in that it was ‘clean’ IP entirely unconnected to her subsequent work in the States.
Is it dead in the water? If so maybe the market ain’t being so stupid here.